Auto-generated from public data. Not the firm's stated position.
OCCIDENT appears to focus on early-stage deep tech and life sciences companies in Europe, with recent portfolio activity suggesting particular interest in specialized biotech applications including oncology therapeutics and medical devices, alongside emerging robotics ventures. The firm's disclosed check size of €1.5M–€3.0M and seed-stage positioning indicate a strategy targeting capital-efficient innovation in healthcare and industrial automation sectors.
Generated 17 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.